Compare SABS & FUND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SABS | FUND |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | United States | Canada |
| Employees | 86 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.8M | 303.4M |
| IPO Year | N/A | N/A |
| Metric | SABS | FUND |
|---|---|---|
| Price | $3.31 | $10.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | ★ 456.5K | 23.3K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.64% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.93 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.85 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $7.39 |
| 52 Week High | $6.60 | $10.47 |
| Indicator | SABS | FUND |
|---|---|---|
| Relative Strength Index (RSI) | 40.23 | 47.01 |
| Support Level | $2.84 | $9.87 |
| Resistance Level | $4.09 | $10.07 |
| Average True Range (ATR) | 0.17 | 0.17 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 7.93 | 14.45 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.